Protein Official symbol | PRDX2 |
Aliases | PRDX2 NKEFB TDPX1 |
Chromosomal Location | 19 |
Length | 198 |
Uniprot ID | P32119 |
EC number | 1.11.1.24 |
Protein family Information(Pfam) | PF10417;PF00578; |
PDB id | 1QMV;5B8A;5B8B;5IJT; |
InterPro ID | IPR000866;IPR024706;IPR019479;IPR036249;IPR013766; |
dbSNP | rs34012472 |
Protein 1 | Protein 2 | Combine Score |
---|---|---|
CDK5 | CDK5R1 | 0.992 |
TXN | PRDX2 | 0.981 |
CDK5 | PRDX2 | 0.929 |
CDK5R1 | PRDX2 | 0.904 |
# | 1020 (CDK5) | 7295 (TXN) | 8851 (CDK5R1) | 7001 (PRDX2) |
---|---|---|---|---|
1020 (CDK5) | 1.00 | 0.42 | 0.70 | 0.42 |
7295 (TXN) | 0.42 | 1.00 | 0.48 | 0.57 |
8851 (CDK5R1) | 0.70 | 0.48 | 1.00 | 0.47 |
7001 (PRDX2) | 0.42 | 0.57 | 0.47 | 1.00 |
Protein Official symbol | Source Organism | Tissue of Expression | Level of hypoxia | Altitude | Duration of experiment | Level of expression | Fold change | Experiment details | geographical location | ethnicity of the patients | Control group | Control (Fold change) | Reference (PMID) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
PRDX2 | Human | Blood | - | 3600 m | Native | upregulated | - | TMT-based proteomic analysis/LC-MS | Central Asia | Tibetans | - | High altitude native vs. low Lander | 30908922 |
PRDX2 | Human | Skeletal muscle | - | 4559 m | 9 day | downregulated | -1.62 | 2-DIGE | Southern Europe | Italians | 1 | Fasting control subjects at laboratory in Copenhagen with no caffeine intake | 18937252 |
PRDX2 | Rat | Plasma | - | 7620 m | 24 hours | downregulated | 1.42 | 2-DE | Northern indo-australian plate | Sprague-dawley rats | 1 | Male SD rats weighing 220g | 24842778 |
PRDX2 | Rat | Plasma | - | 7620 m | 6 hours | upregulated | 0.77 | 2-DE | Northern indo-australian plate | Sprague-dawley rats | 1 | Male SD rats weighing 220g | 24842778 |
TF | TF Entrez | Gene | Gene Entrez | Type | PMID | Database |
---|---|---|---|---|---|---|
SMARCA4 | 6597 | PRDX2 | 7001 | proximal_filtered | 22955619 | TRANSFAC |
SRF | 6722 | PRDX2 | 7001 | proximal_filtered | 22955619 | TRANSFAC |
JUND | 3727 | PRDX2 | 7001 | proximal_filtered | 22955619 | TRANSFAC |
EP300 | 2033 | PRDX2 | 7001 | proximal_filtered | 22955619 | TRANSFAC |
SMARCB1 | 6598 | PRDX2 | 7001 | proximal_filtered | 22955619 | TRANSFAC |
miRTarBase ID | miRNA | Species (miRNA) | Protein Official Symbol | Human Entrez ID | Species (Target Gene) | Experiments | Support Type | References (PMID) |
---|---|---|---|---|---|---|---|---|
MIRT023992 | hsa-miR-1-3p | Homo sapiens | PRDX2 | 7001 | Homo sapiens | Proteomics;Microarray | Functional MTI (Weak) | 18668037 |
MIRT039753 | hsa-miR-615-3p | Homo sapiens | PRDX2 | 7001 | Homo sapiens | CLASH | Functional MTI (Weak) | 23622248 |
MIRT042800 | hsa-miR-339-5p | Homo sapiens | PRDX2 | 7001 | Homo sapiens | CLASH | Functional MTI (Weak) | 23622248 |
MIRT046023 | hsa-miR-125b-5p | Homo sapiens | PRDX2 | 7001 | Homo sapiens | CLASH | Functional MTI (Weak) | 23622248 |
MIRT047661 | hsa-miR-10a-5p | Homo sapiens | PRDX2 | 7001 | Homo sapiens | CLASH | Functional MTI (Weak) | 23622248 |
MIRT732736 | hsa-miR-205-5p | Homo sapiens | PRDX2 | 7001 | Homo sapiens | 2-D Gel Electrophoresis (2DGE)//qRT-PCR//Western blot | Functional MTI | 26633009 |
MIRT732737 | hsa-miR-153-3p | Homo sapiens | PRDX2 | 7001 | Homo sapiens | 2-D Gel Electrophoresis (2DGE)//qRT-PCR//Western blot | Functional MTI | 26633009 |
ID | GO ID | GO Term | GO Type |
---|---|---|---|
7001 | GO:0006979 | response to oxidative stress | GOTERM_BP_DIRECT |
7001 | GO:0034599 | cellular response to oxidative stress | GOTERM_BP_DIRECT |
7001 | GO:0005737 | cytoplasm | GOTERM_CC_DIRECT |
7001 | GO:0045454 | cell redox homeostasis | GOTERM_BP_DIRECT |
7001 | GO:0000302 | response to reactive oxygen species | GOTERM_BP_DIRECT |
7001 | GO:0019430 | removal of superoxide radicals | GOTERM_BP_DIRECT |
7001 | GO:0043066 | negative regulation of apoptotic process | GOTERM_BP_DIRECT |
7001 | GO:0005829 | cytosol | GOTERM_CC_DIRECT |
7001 | GO:0055114 | oxidation-reduction process | GOTERM_BP_DIRECT |
7001 | GO:0008379 | galactosyltransferase activity | GOTERM_MF_DIRECT |
7001 | GO:0042744 | hydrogen peroxide catabolic process | GOTERM_BP_DIRECT |
7001 | GO:0005623 | cell | GOTERM_CC_DIRECT |
7001 | GO:0042981 | regulation of apoptotic process | GOTERM_BP_DIRECT |
7001 | GO:0070062 | extracellular exosome | GOTERM_CC_DIRECT |
7001 | GO:0016209 | antioxidant activity | GOTERM_MF_DIRECT |
Human Entrez ID | KEGG ID | KEGG Term |
---|
Protein Official Symbol | Human Entrez ID | Disease Name | Disease Id | Disease Semantic Type | Semantic score | DSI | DPI | Disease Type |
---|---|---|---|---|---|---|---|---|
PRDX2 | 7001 | Prostatic Neoplasms | C0033578 | Neoplastic Process | 0.31 | 0.535 | 0.759 | group |
PRDX2 | 7001 | Trisomy 21, Meiotic Nondisjunction | C0432417 | Disease or Syndrome | 0.3 | 0.535 | 0.759 | disease |
PRDX2 | 7001 | Pulmonary Fibrosis - from Asbestos Exposure | C2930617 | Disease or Syndrome | 0.3 | 0.535 | 0.759 | disease |
PRDX2 | 7001 | Mammary Neoplasms, Experimental | C0024668 | Experimental Model of Disease; Neoplastic Process | 0.3 | 0.535 | 0.759 | group |
PRDX2 | 7001 | Keloid | C0022548 | Acquired Abnormality | 0.3 | 0.535 | 0.759 | phenotype |
PRDX2 | 7001 | Carcinomatosis | C0205699 | Neoplastic Process | 0.3 | 0.535 | 0.759 | phenotype |
PRDX2 | 7001 | Malignant neoplasm of prostate | C0376358 | Neoplastic Process | 0.34 | 0.535 | 0.759 | disease |
PRDX2 | 7001 | Esophageal Neoplasms | C0014859 | Neoplastic Process | 0.3 | 0.535 | 0.759 | group |
PRDX2 | 7001 | Leukemia, Monocytic, Chronic | C0023466 | Neoplastic Process | 0.3 | 0.535 | 0.759 | disease |
PRDX2 | 7001 | Neoplasm Invasiveness | C0027626 | Pathologic Function | 0.3 | 0.535 | 0.759 | phenotype |
PRDX2 | 7001 | Mammary Carcinoma, Animal | C1257925 | Neoplastic Process | 0.3 | 0.535 | 0.759 | disease |
PRDX2 | 7001 | Osteosarcoma | C0029463 | Neoplastic Process | 0.31 | 0.535 | 0.759 | disease |
PRDX2 | 7001 | Undifferentiated carcinoma | C0205698 | Neoplastic Process | 0.3 | 0.535 | 0.759 | phenotype |
PRDX2 | 7001 | Down Syndrome | C0013080 | Disease or Syndrome | 0.33 | 0.535 | 0.759 | disease |
PRDX2 | 7001 | melanoma | C0025202 | Neoplastic Process | 0.32 | 0.535 | 0.759 | disease |
PRDX2 | 7001 | Carcinoma | C0007097 | Neoplastic Process | 0.3 | 0.535 | 0.759 | group |
PRDX2 | 7001 | Down Syndrome, Partial Trisomy 21 | C0432416 | Disease or Syndrome | 0.3 | 0.535 | 0.759 | disease |
PRDX2 | 7001 | Malignant neoplasm of esophagus | C0546837 | Neoplastic Process | 0.3 | 0.535 | 0.759 | disease |
PRDX2 | 7001 | Myeloid Leukemia | C0023470 | Neoplastic Process | 0.31 | 0.535 | 0.759 | disease |
PRDX2 | 7001 | Animal Mammary Neoplasms | C0024667 | Neoplastic Process | 0.3 | 0.535 | 0.759 | group |
PRDX2 | 7001 | Liver carcinoma | C2239176 | Neoplastic Process | 0.34 | 0.535 | 0.759 | disease |
PRDX2 | 7001 | Asbestosis | C0003949 | Disease or Syndrome | 0.3 | 0.535 | 0.759 | disease |
PRDX2 | 7001 | Anaplastic carcinoma | C0205696 | Neoplastic Process | 0.3 | 0.535 | 0.759 | disease |
PRDX2 | 7001 | Carcinoma, Spindle-Cell | C0205697 | Neoplastic Process | 0.3 | 0.535 | 0.759 | disease |
PRDX2 | 7001 | Trisomy 21, Mitotic Nondisjunction | C0751081 | Disease or Syndrome | 0.3 | 0.535 | 0.759 | disease |
Protein Official Symbol | Human Entrez ID | drug_claim_primary_name | drug_name | drug_chembl_id | interaction_types |
---|